The contraceptive vaginal ring

Seminars in Reproductive Medicine

Volumn 28, Issue 2, 2010, Pages 133-139

  Edwardson, Jill ^a   Jamshidi, Roxanne ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

NuvaRing; Vaginal contraception; Vaginal ring

Indexed keywords

19 NORPROGESTERONE DERIVATIVE; AMOXICILLIN; DESOGESTREL; DOXYCYCLINE; ELCOMETRINE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETONOGESTREL; LEVONORGESTREL; MICONAZOLE; MICONAZOLE NITRATE; NONOXINOL 9; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE DERIVATIVE; RIFAMPICIN; UNCLASSIFIED DRUG;

CONTRACEPTION; DRUG MECHANISM; HUMAN; LIPID METABOLISM; REVIEW; SEXUALITY; VAGINA BLEEDING; VAGINA RING;

CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; DELAYED-ACTION PREPARATIONS; DESOGESTREL; DRUG COMBINATIONS; DRUG INTERACTIONS; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; PROGESTINS; SELF ADMINISTRATION;

EID: 77950542556     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0030-1248138     Document Type: Review

References (40)

1. Timmer C J., Mulders T M. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000 39 (3) 233-242
2. Johansson E DB, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am J Obstet Gynecol 2004 190 (4, suppl) S54-S59
3. Sarkar N N. Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review. Eur J Contracept Reprod Health Care 2003 8 (4) 217-224
4. Rowlands S. New technologies in contraception. BJOG 2009 116 (2) 230-239
5. Mulders T M., Dieben T O. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001 75 (5) 865-870
6. van den Heuvel M W., van Bragt A JM, Alnabawy A KM, Kaptein M CJ. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005 72 (3) 168-174
7. Duijkers I J., Klipping C, Verhoeven C H., Dieben T O. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. Hum Reprod 2004 19 (11) 2668-2673
8. Mulders T M., Dieben T OM, Bennink H J. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002 17 (10) 2594-2599
9. Roumen F J., Apter D, Mulders T M., Dieben T O. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001 16 (3) 469-475
10. Barnhart K T., Timbers K, Pretorius E S., Lin K, Shaunik A. In vivo assessment of NuvaRing placement. Contraception 2005 72 (3) 196-199
11. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004 104 (3) 555-563
12. Creinin M D., Meyn L A., Borgatta L et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol 2008 111 (2 Pt 1) 267-277
13. Dieben T O., Roumen F J., Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002 100 (3) 585-593
14. Verhoeven C H., Dieben T O. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. Contraception 2004 69 (3) 197-199
15. Oddsson K, Leifels-Fischer B, de Melo N R. et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 2005 71 (3) 176-182
16. Novk A, de la Loge C, Abetz L, van der Meulen E A. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 2003 67 (3) 187-194
17. Oddsson K, Leifels-Fischer B, Wiel-Masson D et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod 2005 20 (2) 557-562
18. Milsom I, Lete I, Bjertnaes A et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006 21 (9) 2304-2311
19. Brucker C, Karck U, Merkle E. Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany. Eur J Contracept Reprod Health Care 2008 13 (1) 31-38
20. Camacho D P., Consolaro M E., Patussi E V., Donatti L, Gasparetto A, Svidzinski T I. Vaginal yeast adherence to the combined contraceptive vaginal ring (CCVR). Contraception 2007 76 (6) 439-443
21. Roumen F J., op ten Berg M M., Hoomans E H. The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands. Eur J Contracept Reprod Health Care 2006 11 (1) 14-22
22. Jensen J T., Burke A E., Barnhart K T., Tillotson C, Messerle-Forbes M, Peters D. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception 2008 78 (6) 451-458
23. Tuppurainen M, Klimscheffskij R, Venhola M, Dieben T O. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study. Contraception 2004 69 (5) 389-394
24. O'Connell K J., Osborne L M., Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. Contraception 2005 72 (5) 323-327
25. Merki-Feld G S., Hund M. Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care 2007 12 (3) 240-247
26. Dickinson B D., Altman R D., Nielsen N H., Sterling M L., Council on Scientific Affairs, American Medical Association. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001 98 (5 Pt 1) 853-860
27. Dogterom P, van den Heuvel M W., Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. Clin Pharmacokinet 2005 44 (4) 429-438
28. Haring T, Mulders T M. The combined contraceptive ring NuvaRing and spermicide co-medication. Contraception 2003 67 (4) 271-272
29. Verhoeven C H., van den Heuvel M W., Mulders T M., Dieben T O. The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. Contraception 2004 69 (2) 129-132
30. Sulak P J., Smith V, Coffee A, Witt I, Kuehl A L., Kuehl T J. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol 2008 112 (3) 563-571
31. Miller L, Verhoeven C H., Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol 2005 106 (3) 473-482
32. Westhoff C, Heartwell S, Edwards S et al. Initiation of oral contraceptives using a quick start compared with a conventional start: a randomized controlled trial. Obstet Gynecol 2007 109 (6) 1270-1276
33. Schafer J E., Osborne L M., Davis A R., Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception 2006 73 (5) 488-492
34. Quick start initiation of the contraceptive vaginal ring in adolescents. ClinicalTrials.gov. ClinicalTrials.gov identifier NCT00369967 Available at: http://www.clinicaltrials.gov/ct2/show/NCT00369967?term=%22vaginal+rings%22& rank=7 Accessed October 13, 2009
35. Massai R, Miranda P, Valds P et al. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception 1999 60 (1) 9-14
36. Massai R, Quinteros E, Reyes M V. et al. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. Contraception 2005 72 (5) 352-357
37. Study to evaluate the safety and efficacy of two contraceptive vaginal rings delivering a daily dose of 1500 or 2500 mcg of CDB-2914. ClinicalTrials.gov. ClinicalTrials.gov identifier NCT00791297. November 13, 2008 Available at: http://www.clinicaltrials.gov/ct2/show/NCT00791297?term= %22vaginal+rings%22&rank=5 Accessed October 13, 2009
38. Silvin I, Mishell D R. Jr, Alvarez F et al. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception 2005 71 122-129
39. Study of the safety, efficacy and cycle control of a contraceptive vaginal ring. ClinicalTrials.gov. ClinicalTrials.gov identifier NCT00455156 Available at: http://www.clinicaltrials.gov/ct2/show/NCT00455156?term= %22vaginal+rings%22&rank=8 Accessed October 13, 2009
40. Safety and efficacy of a contraceptive vaginal ring delivering Nestorone and ethinyl estradiol. ClinicalTrials.gov. ClinicalTrials.gov Identifier NCT00263341 Available at: http://www.clinicaltrials.gov/ct2/show/NCT00263341? term=%22vaginal+rings%22&rank=10 Accessed October 13, 2009